Education
About Us
Working with TipRanks
Follow Us
Yunkang Group Limited (HK:2325)
:2325
2325 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.10 - HK$10.80
Previous CloseN/A
Volume10.00K
Average Volume (3M)137.13K
Market Cap
HK$2.36B
Enterprise ValueHK$8.56B
Total Cash (Recent Filing)HK$1.70B
Total Debt (Recent Filing)¥1.18B
Price to Earnings (P/E)―
Beta0.14
Next EarningsN/A
EPS EstimateN/A
Last Dividend Ex-Date
Jul 04, 2024Dividend Yield0.53%
Share Statistics
EPS (TTM)-1.44
Shares Outstanding621,250,500
10 Day Avg. Volume122,455
30 Day Avg. Volume137,130
Financial Highlights & Ratios
PEG Ratio-5.78
Price to Book (P/B)3.07
Price to Sales (P/S)0.00
P/FCF Ratio-36.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Yunkang Group Limited News
PremiumCompany Announcements
Yunkang Group Limited AGM Resolutions Unanimously Approved
PremiumCompany Announcements
Yunkang Group Limited Forms Nomination Committee to Strengthen Governance
PremiumCompany Announcements
Yunkang Group Limited Announces Annual General Meeting and Key Resolutions
PremiumCompany Announcements
Yunkang Group Appoints Dr. Dong Min as Independent Director
PremiumCompany Announcements
Yunkang Group Limited Announces Board Composition and Roles
PremiumCompany Announcements
Yunkang Group Reports Significant Financial Losses for 2024
PremiumCompany Announcements
Yunkang Group Reschedules Board Meeting for Annual Results ApprovalPremiumCompany Announcements
Yunkang Group Schedules Board Meeting to Approve Annual Results2325 FAQ
What was Yunkang Group Limited’s price range in the past 12 months?
Yunkang Group Limited lowest stock price was HK$2.10 and its highest was HK$10.80 in the past 12 months.
What is Yunkang Group Limited’s market cap?
Yunkang Group Limited’s market cap is HK$2.36B.
When is Yunkang Group Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Yunkang Group Limited’s earnings last quarter?
Yunkang Group Limited released its earnings results on Aug 28, 2024. The company reported -HK$0.23 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.23.
Is Yunkang Group Limited overvalued?
According to Wall Street analysts Yunkang Group Limited’s price is currently Overvalued.
Does Yunkang Group Limited pay dividends?
Yunkang Group Limited pays a Annually dividend of HK$0.02 which represents an annual dividend yield of 0.53%. See more information on Yunkang Group Limited dividends here
What is Yunkang Group Limited’s EPS estimate?
Yunkang Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yunkang Group Limited have?
Yunkang Group Limited has 621,250,500 shares outstanding.
What happened to Yunkang Group Limited’s price movement after its last earnings report?
Yunkang Group Limited reported an EPS of -HK$0.23 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Yunkang Group Limited?
Currently, no hedge funds are holding shares in HK:2325
Yunkang Group Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.03%
12-Months-Change
Fundamentals
Return on Equity
-48.48%
Trailing 12-Months
Asset Growth
-31.12%
Trailing 12-Months
Company Description
Yunkang Group Limited
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction and screening tests; and routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. In addition, the company offers diagnostic testing services for financial institutions and insurance companies, including personalized diagnostic testing, medical report consultation, and hospital referral services; information technology, medical logistics, and medical equipment procurement; healthcare technology development; and project investment. It provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.
Technical Analysis
MicroPort CardioFlow Medtech Corp.
―
Beijing Airdoc Technology Co. Ltd. Class H
―
C-MER Eye Care Holdings Limited
―
Mega Genomics Limited
―